Gemfibrozil attenuates doxorubicin induced toxicity in renal tissues of male rats by reducing the oxidative insult and inflammation

Hosseinzadeh, Azam; Goudarzi, Mehdi; Fatemi, Iman; Khodayar, Mohammad Javad; Mehrzadi, Saeed; Khalili, Hamidreza; Karimi, Meghdad

doi:10.1080/10520295.2020.1730967

Cited by 12 publications

(10 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The beneficial effects of GFZ on potentiating the antioxidant defense system and reducing antioxidative parameters have been shown previously in other physiological systems. GFZ increased the activities of SOD and GPx and reduced MDA levels in renal and cardiac tissues of rats treated with doxorubicin [36, 37]. Moreover, it has been demonstrated that pretreatment with GFZ reduces the hippocampal level of MDA as well as the activity of SOD in rats with acute restraint stress [38].…”

Section: Discussionmentioning

confidence: 99%

Gemfibrozil, a lipid‐lowering drug, reduces anxiety, enhances memory, and improves brain oxidative stress in d‐galactose‐induced aging mice

Hakimizadeh

Zamanian

Борисов

et al. 2022

Fundamemntal Clinical Pharma

Self Cite

View full text Add to dashboard Cite

Gemfibrozil (GFZ) is a lipid‐lowering drug with several other effects, such as antioxidant and anti‐inflammatory activities. In the current study, chronic d‐galactose treatment (d‐gal, 150 mg/kg/day; i.p., 6 weeks) induced a model of accelerated aging in male mice and was used to study the behavioral, anti‐oxidative, and neuroprotective effects of GFZ (100 mg/kg/day; p.o.). Anxiety‐like behaviors were assessed using the elevated plus‐maze while working memory was measured by spontaneous alternation in a Y‐maze. Brain oxidative stress was determined by measuring malondialdehyde (MDA) levels, superoxide dismutase (SOD), and glutathione peroxidase (GPx) activities. Neuropathological evaluation of the brain with hematoxylin–eosin and Masson's trichrome staining was also performed. The results demonstrated that the anxious‐like phenotype and the cognitive impairments observed in d‐gal‐treated mice could be prevented in those animals coadministered with GFZ. Besides, the decrease in SOD and GPx antioxidant enzymatic activities and increase of MDA levels were also prevented in the brains of d‐gal plus GFZ treated mice. Preliminary hematoxylin–eosin staining also suggested neuroprotective effects of GFZ. The results of Masson's trichrome staining showed no evidence of fibrosis in brain sections of different experimental groups. The current data provide novel insights into GFZ in the d‐galactose‐induced aging mouse model that open promising future research lines to determine inflammatory mediators and cell signaling underlying these effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Gemfibrozil, a lipid‐lowering drug, reduces anxiety, enhances memory, and improves brain oxidative stress in d‐galactose‐induced aging mice

Hakimizadeh

Zamanian

Борисов

et al. 2022

Fundamemntal Clinical Pharma

Self Cite

View full text Add to dashboard Cite

show abstract

“…Chronic oxidative stress is involved in aging-induced organ failure [45]. MDA is a highly reactive end-product of lipid peroxidation [46,47], causing functional and pathological changes in the kidney and liver [32,48,49]. CaD has been shown to reduce lipid peroxidation in isolated human varicose veins [50].…”

Section: Discussionmentioning

confidence: 99%

Calcium dobesilate protects against d‐galactose‐induced hepatic and renal dysfunction, oxidative stress, and pathological damage

Hakimizadeh

Heidari

Giménez‐Llort

et al. 2022

Fundamemntal Clinical Pharma

Self Cite

View full text Add to dashboard Cite

Calcium dobesilate (CaD) is used for the treatment of diabetic retinopathy and nephropathy. This agent exerts antioxidant effects. In the present study, we evaluated the protective effects of oral administration of CaD against hepatorenal damages in a mice model of aging induced by D-galactose (Dgal). We used 28 male albino mice, which equally and randomly were divided into four groups as follows: intact, aging (D-gal at the dose of 500 mg/kg, p.o.), aging + CaD 50 (D-gal plus CaD at the dose of 50 mg/kg), and aging + CaD 100 (D-gal plus CaD at the dose of 100 mg/kg, p.o.). All drugs were administered orally once a day for 42 days. The liver and kidney damages were evaluated by measuring mass indices, levels of serum creatinine and blood urea nitrogen, and activities of serum alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase and by histopathological evaluation. Moreover, hepatic and renal tissue oxidant/ antioxidant markers (malondialdehyde, superoxide dismutase, catalase, and glutathione peroxidase) were measured. The results showed that D-gal treatment induced significant oxidative stress in the kidney and liver that was paralleled by dysfunctions and histological alterations of these organs. CaD significantly improved the liver and kidney indices, implemented functional capacity of the liver and kidney, as well as decreased oxidative stress

show abstract

“…Existe evidencia indirecta del compromiso tubular proximal, como la encontrada en el estudio de Hosseinzadeh et al [5], en el que se usó gemfibrozil con el fin de atenuar el daño renal inducido por estrés oxidativo e inflamación en ratas sometidas al uso de doxorrubicina. Así pues, se evidenció una disminución del 9 % en el daño tubular proximal con respecto a los animales que se expusieron al quimioterapéutico exclusivamente.…”

Section: Discussionunclassified

“…Existe literatura con menor fuerza de la evidencia sobre otros quimioterapéuticos que se encuentran asociados a SF, entre estos se destacan el metotrexato y la doxorrubicina que, a través de modelos animales, sustentan su plausibilidad biológica. Lo anterior, principalmente, bajo fenómenos de estrés oxidativo que derivan en peroxidación lipídica, liberación excesiva de óxido nítrico, aumento de la permeabilidad en los capilares glomerulares y degeneración tubular en zonas de alta susceptibilidad a este fenómeno como el túbulo contorneado proximal [4,5].…”

Section: Introductionunclassified

Síndrome de Fanconi por agentes quimioterapéuticos: serie de casos y revisión de la literatura

Valbuena¹,

Sierra²,

Serrano³

et al. 2022

Rev. Colomb. Nefrol.

View full text Add to dashboard Cite

Introducción: múltiples agentes quimioterapéuticos que se usan comúnmente pueden causar síndrome de Fanconi (SF) completo o parcial. El SF es una tubulopatía proximal que produce alteraciones electrolíticas y ácido-básicas, donde se evidencia pérdida de glucosa, aminoácidos, calcio, fósforo, potasio, ácido úrico y se produce acidosis metabólica por pérdida de bicarbonato. El SF usualmente no es reportado y muchas veces no se realiza el diagnóstico. Objetivo: resaltar la importancia del monitoreo urinario y sérico en pacientes que estén sometidos a quimioterapia, así como describir la literatura reciente acerca de la asociación entre agentes quimioterapéuticos y síndrome de Fanconi parcial o completo. Presentación de los casos: se presenta una serie de casos de pacientes pediátricos oncológicos con función renal preservada, donde se produjeron diferentes manifestaciones de nefrotoxicidad tubular proximal secundaria a agentes quimioterapéuticos como antimetabolitos, agentes alquilantes y antraciclinas. Discusión y conclusión: el espectro del SF puede ir de una tubulopatía proximal generalizada o completa a alteraciones parciales en la reabsorción de electrolitos. Se debe reconocer la importancia del monitoreo sérico y urinario en pacientes con lesiones tumorales que van a ser sometidos a quimioterapias con agentes potencialmente nefrotóxicos; asimismo, tener en cuenta la dosis, la frecuencia y la combinación de agentes quimioterapéuticos, con el fin de prevenir y tratar complicaciones de toxicidad renal, incluyendo SF completo o parcial.

show abstract

Gemfibrozil attenuates doxorubicin induced toxicity in renal tissues of male rats by reducing the oxidative insult and inflammation

Cited by 12 publications

References 31 publications

Gemfibrozil, a lipid‐lowering drug, reduces anxiety, enhances memory, and improves brain oxidative stress in d‐galactose‐induced aging mice

Gemfibrozil, a lipid‐lowering drug, reduces anxiety, enhances memory, and improves brain oxidative stress in d‐galactose‐induced aging mice

Calcium dobesilate protects against d‐galactose‐induced hepatic and renal dysfunction, oxidative stress, and pathological damage

Síndrome de Fanconi por agentes quimioterapéuticos: serie de casos y revisión de la literatura

Contact Info

Product

Resources

About